Large-scale sensitivity screening of cancer cell lines and glioblastoma patient-derived cells further provided compelling evidence that Abemaciclib sensitivity highly correlates with the c-Met inhibitor crizotinib and cabozantinib. The gene discussed is MET; the disease is cancer.